Medicinal Chemistry

Advances in the Inhibitors of Janus Kinase

Abstract

Jun-Jie J Jiang, Xiao-Ying Wang, Yv Zhang, Yi Jin and Jun Lin

The janus kinases (JAKs) comprise an important class of non-receptor protein tyrosine kinases. Cytokine and receptor binding can cause the activation of JAKs, and then activate the "signal transcripts and transcriptional activator”, making JAK enter the nucleus to induce target gene expression. JAKs regulate inflammatory diseases, bone marrow hyperplasia and a variety of malignant tumours. Using JAKs inhibitors as the therapy for organ transplantation and immune disease has a very important significance. In recent years, many of the JAKs inhibitors have been developed one after another. Pan JAKs inhibitor and selective JAK2 or JAK3 inhibitor research progress are reviewed in this article